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The lipid post-translational modification S-palmitoylation is a vast develop-
ing field, with the modification itself and the enzymes that catalyse the
reversible reaction implicated in a number of diseases. In this review, we
discuss the past and recent advances in the experimental tools used in this
field, including pharmacological tools, animal models and techniques to
understand how palmitoylation controls protein localisation and function.
Additionally, we discuss the obstacles to overcome in order to advance the
field, particularly to the point at which modulating palmitoylation may be
achieved as a therapeutic strategy.
Introduction
Lipid modifications
Post-translational modifications (PTMs) allow
immense diversity in biological systems, often control-
ling substrate localisation, stability and function, and
must be tightly regulated in order to maintain cell
health. Over 400 chemically distinct covalent PTMs
have been described to date, adding huge chemical
complexity to the structure and function of the pro-
teome [1]. Our understanding of the unique PTM pro-
files of individual proteins can improve knowledge of
how to target them for therapeutic benefit. In the
1950s, the first evidence of covalent lipid transfer to a
proteins in the brain was noted [2], but it was not until
decades later that the theory of lipids as an essential
component of protein trafficking gained traction.
Now, several lipid modifications have been identified,
many of which are involved in regulating integration
and association of substrates with membranes through
increasing hydrophobicity (Fig. 1) [3]. This is not done
in a random fashion as initially thought, but utilising
distinct membrane microdomains, known as lipid rafts,
where the increased membrane fluidity may influence
trafficking and protein–protein interactions, and there-
fore, lipid modified proteins have become a subject of
great interest in recent years [4].
As such, it is estimated between 25 and 40% of sub-
strates are modified by lipids in some way, making
them one of the most common types of PTM and as
such, a concerted effort has been made to classify and
characterise them [5]. In mammalian cells, many types
of fatty acylation (involving the addition of fatty acids
between eight and twenty carbons in length) involve
irreversible modifications of proteins. This includes N-
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terminal myristoylation of a glycine by a 14-carbon
(C14:0) myristoyl group, either co- or post-translation-
ally, and has been implicated as a key step in many
immune cell signalling cascades [6]. Similarly, prenyla-
tion provides a hydrophobic, membrane attracted C
terminus through the enzymatic addition of farnesyl
(C15:0) or geranylgeranyl (C20:0) to a cysteine residue,
and the modification is now implicated as being dys-
regulated in several diseases including cancer [7].
Prenylation is not the only lipid cysteine modification,
with their reactive sulfhydryl groups open to thioester
linkage through S-acylation. These acyl additions can
range in length from 16–20 carbons, with the C16:0,
often palmitoyl derived from palmitoyl-CoA (S-palmi-
toylation), being the most common form. In fact, S-
acylation and S-palmitoylation, in particular, have
attracted much interest in the PTM field due to its
reversible, enzyme-driven nature and wide ranging
effects on substrate localisation and activity for both
integral membrane and soluble proteins, with more
than 10% of the proteome predicted to be targeted by
S-palmitoylation [8].
S-acylation enzymology
Initially, studies into the G protein Gia1, the down-
stream effector of many important receptors, saw cys-
teine 3 (C3) auto-palmitoylated in the presence of
palmitoyl-CoA. This was interpreted to mean that
palmitoylation may be a spontaneous modification
dependent on local fatty acid concentration, and there-
fore, modulation for therapeutic benefit would be chal-
lenging [9]. Progress in the field was therefore slow,
with potential enzymes involved difficult to identify,
even resulting in false positives [10]. Gradually evi-
dence began emerging that palmitate turnover could
be modulated, for example by isoproterenol stimula-
tion of Gas [11]. In 2002, a seminal study in yeast
revealed that S-palmitoylation of Ras2 was catalysed
by a zinc-finger motif containing enzyme, now known
as a zDHHC-palmitoyl acyltransferase (zDHHC-
PAT), named due to a conversed aspartate-histidine-
histidine-cysteine motif in the enzyme active site
[12,13]. These enzymes are multidomain integral mem-
brane proteins, usually with intracellular N- and C-ter-
minals, the latter of which is often long, poorly
conserved and disordered, as well as a conserved ~ 55
amino acid cysteine-rich region between transmem-
brane domains 2 and 3 [14]. To date, 23 human iso-
forms have been identified and a study utilising GFP-
tagged versions transfected and stained in HEK293
cells revealed distinct localisation patterns throughout
the secretory pathway. Interestingly, some zDHHC-
PATs show specific subcellular localisation, that is
zDHHC5 to the plasma membrane, zDHHC7 and
zDHHC8 to the Golgi and DHHC6 and DHHC13 to
the endoplasmic reticulum (ER), while others appear
in more than one location (Fig. 2) [15,16]. Together,
these enzymes regulate the palmitoylation of substrates
in every class of protein, in every tissue investigated to
date, some of which, as will be discussed, having
important physiological and pathophysiological conse-
quences [17].
Palmitoylation can be reversed by slow hydrolysis of
the thioester or catalytically by removal of the palmi-
toyl by soluble acyl thioesterases. Through investiga-
tion of H-Ras and Ga depalmitoylation in the 1990s,















Fig. 1. Lipid post-translational modifications.
Proteins can be subjected to multiple forms
of lipid post-translational modification.
These include cysteine modifications S-
palmitoylation (C16:0), which forms a
reversible thioester, and S-farnesylation
(C15:0) and geranylgeranylation (C20:0),
which form an irreversible thioether. Amide
groups of lysines, glycines and N-terminal
portions of proteins can be subjected to
irreversible lipid modifications in the form of
N-palmitoylation (C16:0; lysine/N-terminal)
and N-myristoylation (C14:0; glycine).
Adapted using information from
(Chamberlain and Shipston, 2015). [29]
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identified. Subsequent bioinformatics analysis revealed
the existence of acyl protein thioesterase 2 (APT2),
sharing ~ 68% homology to APT1 [18,19]. Both are
members of the a/b serine hydrolase family, with
active site serines crucial for their enzymatic activity,
and are found localised in the cytosol as well as lyso-
somes [20]. Although thought to be the only method
of enzymatic depalmitoylation, in recent years several
studies have revealed other acyl thioesterases, such as
a family of ABHD17 serine hydrolases that can
remove palmitoyls from N-Ras where APT1 and
APT2 could not [21], and more recently ABHD10, the
first identified mitochondrial localised thioesterase,
shedding light on the emerging field of mitochondrial
palmitoylation [22].
Palmitoylation as a therapeutic target
The dynamic process of palmitoylating and depalmi-
toylating target proteins has led to great interest in
understand how this PTM changes in disease states,
and whether it may be tractable to target using small
molecules. Until recently, the three main fields in
which research has focussed were cancer, neurosciences
and cardiovascular disease (for an overview see Fraser,
et al. 2020 [23]).
Cancer
Numerous G proteins must be palmitoylated, both to









zDHHC2, -3, -4, -7
-8, -9, -12, -15, -17
-18, -22
zDHHC1, -2, -6, -9, 
-10/11, -11/23, -12, 
-13, -14, -16, -19, -22
Fig. 2. Localisation of zDHHC-palmitoyl
acyltransferases. zDHHC-palmitoyl
acyltransferases (zDHHC-PATs) are located
throughout the secretory pathway in the
endoplasmic reticulum, Golgi apparatus and
plasma membrane, with some solely
located in one component and others found
in multiple locations (for detailed information
refer to Ohno, et al. 2006 [15] with updated
information from Korycka, et al. 2012 [159]).
zDHHC-PATs palmitoylate cysteine
sulfhydryl groups (SH) by transferring
palmitoyl (C16) from palmitoyl-CoA, often
leading to targeting of the palmitoyl and
attached target protein to intracellular
membranes.
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within microdomains [24]. The best-studied of these in
the context of human disease are the small G proteins
K-ras, H-ras and N-ras, which between them regulate
a diverse array of intracellular signalling networks. A
quarter of human cancers are driven by mis-sense
mutations in ras isoforms [25], and since ras signalling
is intimately linked to its membrane attachment the
ras lipid anchors have generated considerable interest.
K-ras4a and N-ras are palmitoylated at a single cys-
teine in their C-terminal hypervariable region, and H-
ras at two cysteines in the same region. zDHHC9 has
long been known to palmitoylate ras isoforms, and
N-ras-mediated oncogenic transformation of cells is
impeded in the absence of zDHHC9 [26]. However,
promiscuity and redundancy in zDHHC-PAT rela-
tionships with their substrates is a common feature in
this field: ras isoforms remain palmitoylated and
oncogenic in the absence of zDHHC9, and indeed
even following genetic deletion of numerous zDHHC-
PATs [27]. Experimental strategies that target one
individual zDHHC-PAT consequently have a limited
impact on palmitoylation of a target protein, and the
therapeutic tractability of zDHHC-PATs themselves is
therefore questionable. On the other hand, as we
develop our understanding of the ‘substrate recogni-
tion rules’ for zDHHC-PATs, small molecules target-
ing the feature(s) of a palmitoylated protein that are
recognised by its zDHHC-PATs offer exciting poten-
tial to manipulate the palmitoylation of only that par-
ticular protein.
Neurosciences
The neurological phenotypes associated with the vari-
ous zDHHC-PAT knockout models characterised to
date (described below) highlight the importance of
palmitoylation in the formation and maintenance of
synapses. For example, the importance of the interac-
tion between zDHHC5 and PSD-95 in the postsynap-
tic density is emphasised by the defects in
hippocampal-dependent learning and memory
observed in zDHHC5 knockout animals [28]. Palmi-
toylation influences synaptic plasticity, and impor-
tantly, its dysregulation has been associated with
Huntington’s disease, with zDHHC13 and zDHHC17
also implicated [28,29]. Interestingly, the finding that
PSD-95 itself is palmitoylated by zDHHC2 [30] but
not by zDHHC5 emphasises the multiplicity of
zDHHC-PAT contributions to synapse assembly.
Notably, this also highlights that colocalisation should
not be assumed to be sufficient to infer an enzyme–
substrate relationship between a palmitoylated protein
and a zDHHC-PAT.
Given that 41% of synaptic proteins are palmitoy-
lated [31], it is little wonder that mutations in a num-
ber of zDHHC-PATs ultimately lead to human
neurological disorders [32]. Loss of function of
zDHHC9, for example, is associated with X-linked
intellectual disability [33] and epilepsy [34], while
mutations in zDHHC15 [35] and zDHHC8 [36] are
linked to X-linked mental retardation and schizophre-
nia, respectively. Recent work has established that the
ability of zDHHC9 to palmitoylate the small G pro-
teins N-ras and TC10 is a key step in promoting den-
dritic growth and synapse formation. [37] In the
absence of zDHHC9, excitatory synapses dominate,
which leads to seizure activity. Ultimately, then this
zDHHC-PAT maintains the balance between excita-
tory and inhibitory neurotransmission in the hip-
pocampus, and both zDHHC9 and its substrates
represent candidates for therapeutic intervention in
this group of patients.
Cardiovascular system
Palmitoylation in vascular health and disease
Palmitoylation of signalling molecules and ion trans-
porters influences the physiology of both cardiac and
vascular tissue. Although relatively few investigations
have considered the role of palmitoylation in control-
ling the behaviour of vascular smooth muscle, our
understanding of the importance of palmitoylation in
the control of vascular tone has been aided by a num-
ber of studies focused on the endothelial cell layer that
lines the vasculature, regulating vessel tone and there-
fore blood pressure. Central to the relationship
between endothelial cells and vascular smooth muscle
is endothelial nitric oxide synthase (eNOS), which
must be palmitoylated in order to localise to caveolae
in endothelial cells [38]. Palmitoylation-deficient eNOS
produces less nitric oxide (NO) than the wild-type
enzyme [39]. Interestingly, palmitoylation of eNOS
in vivo is reported to be controlled in part by fatty acid
availability. Genetic deletion of fatty acid synthase
from endothelial cells impairs eNOS palmitoylation
and NO production, while insulin resistance and fatty
acid synthase downregulation lead to reduced eNOS
palmitoylation, less NO production and endothelial
dysfuncton [40]. This paradigm that fatty acid avail-
ability controls protein palmitoylation in vivo has not
been widely explored. Given the relative paucity of
knowledge regarding the control of zDHHC-PAT
activity, it will be interesting to address in the future
whether co-localisation of zDHHC-PATs, their sub-
strates and fatty acid/fatty acyl-CoA synthesising
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enzymes represents a general mechanism to control
protein palmitoylation either globally, or in specific
cellular microdomains.
The importance of protein palmitoylation in
endothelial cell function was emphasised in a recent
study that evaluated the impact of endothelial-specific
deletion of the acylthioesterase APT1. Vascular remod-
elling after hindlimb ischaemia was blunted in the
absence of endothelial APT1, a defect rescued by
expressing mutant forms of R-ras, in which the
hydrophobicity of the hypervariable region containing
the palmitoylation sites was modified. Importantly, R-
ras palmitoylation was also found to be enhanced by
hyperglycaemia, which reduced APT-1 acetylation and
impaired its enzymatic activity [41]. The impact of
serum/extracellular glucose concentrations on palmi-
toylation of other APT-1 substrates remains to be
determined, but it is an important consideration given
most formulations of cell culture media contain supra-
physiological glucose. This study also highlights an
important aspect of palmitoylation in the regulation of
protein function that is sometimes neglected by
researchers: the importance of palmitate cycling on a
substrate protein for its function [42]. In the case of
R-ras, APT1 deficiency led to the accumulation of
palmitoylated R-ras, but this did not enhance R-ras-
mediated signalling. Other proteins also require palmi-
tate cycling for function [43]. As will be discussed,
experimental approaches that offer a snapshot of
‘palmitoylation levels’ cannot give sufficient insight
into palmitoylation cycling on a protein of interest.
Alongside APT1, the PAT zDHHC21 has emerged
as a key regulator of endothelial cell function.
Although multiple zDHHC-PATs are capable of
palmitoylating eNOS, only inhibition of zDHHC21
impairs eNOS-mediated NO production, placing this
enzyme as a key nodal point in the regulation of blood
pressure by the vascular endothelium [39]. Other
endothelial substrates for zDHHC21 include phospho-
lipase b1 and PECAM1, which regulate the integrity
of the endothelial barrier and trans-endothelial migra-
tion of leucocytes, respectively. Transgenic mice lack-
ing zDHHC21 are remarkably resistant to endothelial
dysfunction caused by acute injury [44]. Ultimately
then, zDHHC21 regulates inflammation, a process of
central importance to a host of acute and chronic dis-
eases, and is an attractive therapeutic target for anti-
inflammatory agents.
Palmitoylation in cardiac function
The rhythmic release and removal of calcium from the
cytoplasm of ventricular myocytes by a myriad of ion
channels and transporters controls contraction and
relaxation of the heart. The co-ordinated regulation of
these channels and transporters is consequently essen-
tial for life, is established to be defective in numerous
cardiac diseases and is regulated by dynamic palmitoy-
lation (for an excellent review on this topic, see Essan-
doh, et al. 2020 [45]). In essence, all direct contributors
to cardiac electrical excitability and calcium handling
are palmitoylated (Fig. 3), from the voltage gated
sodium channel Nav1.5 [46] that initiates the cardiac
action potential, to L-type calcium channel subunits
that mediate calcium influx into myocytes [47], to cal-
cium reuptake (SERCA/phospholamban [48]) and
removal (sodium calcium exchanger, NCX1 [49–55])
mechanisms and the ubiquitous Na/K ATPase [56–59],
which maintains ion gradients across the sarcolemma.
Palmitoylation of the cardiac ryanodine receptor
RyR2, which is central to calcium-induced calcium
release from intracellular stores, has not yet been
reported, but it is notable that activity of the skeletal
muscle isoform RyR1 is enhanced when it is palmitoy-
lated [60].
The cell surface acyl transferase zDHHC5 is the best
characterised of the cardiac zDHHC-PATs and is
responsible for palmitoylation and regulation of at
least two ion transporters in the cardiac sarcolemma.
Inactivation of the cardiac sodium/calcium exchanger
NCX1, responsible for cellular Ca efflux at the end of
the contractile cycle, is controlled by zDHHC5 in car-
diac muscle. The NCX1 inactivation process is medi-
ated by a small polybasic region of its large regulatory
loop, XIP, which is usually sequestered by the anionic
phospholipid PIP2. PIP2 hydrolysis leading to the
release of XIP leads to efficient NCX1 inactivation
only when it is palmitoylated; in essence, palmitoyla-
tion sensitises NCX1 to PIP2 [52,55]. Our understand-
ing of the ‘how, when and where’ of NCX1 regulation
by palmitoylation has expanded considerably recently.
NCX1 palmitoylation is promoted by the presence of
an amphipathic a-helix on the C-terminal side of the
NCX1 palmitoylation site. Substitutions on the hydro-
philic face of the helix reduce NCX1 palmitoylation,
suggesting this face is recognised by the NCX1 palmi-
toylating enzymes [53,54]. Supporting this observation,
insertion of this a-helix into a nonpalmitoylated pro-
tein is sufficient to direct its palmitoylation, but inter-
estingly the same helix also affinity purifies the
depalmitoylating enzyme APT1 from tissue lysates –
suggesting it is also responsible for recruiting the
NCX1 thioesterase [49]. Using FRET probes inserted
into the regulatory intracellular loop of NCX1, we
found that palmitoylation restructures existing NCX1
dimers to promote NCX1-NCX1 FRET. The structural
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rearrangement caused by NCX1 palmitoylation pro-
motes XIP engagement with its binding site close to the
NCX1 palmitoylation site, which explains the molecu-
lar basis by which palmitoylation promotes NCX1
inactivation [49]. While the physiological role of NCX1
inactivation has remained enigmatic, the finding that
NCX1 sensitivity to inactivation is tuned by palmitoy-
lation, and that this ultimately alters transmembrane
Ca fluxes and modifies steady-state intracellular Ca
[49,51], implies inactivation is a universal means to
tune NCX1 mediated calcium fluxes in multiple tissues.
zDHHC5 recruitment and palmitoylation of NCX1
relies on a different amphipathic a-helix, positioned
after the zDHHC5 fourth transmembrane domain,
which is also the site of interaction of the cardiac Na/
K ATPase (NKA) and the zDHHC5 accessory pro-
teins Golga7b [61] and Golga7 [62]. The cardiac NKA
is regulated by a small accessory subunit phospholem-
man (PLM), which is both palmitoylated and phos-
phorylated in cardiac muscle. Phosphorylation of
PLM by protein kinases A and C at serines 63, 68 and
69 activates NKA, while it is inhibited by palmitoyla-
tion of PLM by zDHHC5, principally at cysteine 40
[56]. PLM recognition and palmitoylation by zDHHC5
rely on a protein–protein interaction between the




















Fig. 3. Cardiac excitation contraction coupling. Arrival of an action potential (AP) at the sarcolemma results in activation of voltage gated
sodium channels (Na(v)1.5) located there, allowing sodium to enter the cell. The subsequent increase in depolarisation activates L-type
voltage gated calcium channels (Ca(v)1.2) located in the cardiomyocyte T-tubules, specialised invaginations that allow propagation of signal
throughout the cell, allowing calcium ions to enter and bind to closely located ryanodine receptors (RYR) on the sarcoplasmic reticulum (SR),
the internal calcium store of the cell. This triggers further calcium release from the SR which binds to the contractile machinery of the cell
and triggers the sequence of events that will result in shortening of the cell and systole. At the end contraction, calcium is removed from
the cell to return it to its resting state, mainly through the sarcoplasmic reticulum Ca2+ATPase (SERCA), controlled by accessory protein
phospholamban (PLB) back into the SR, and is also expelled from the cell via the Na+/Ca2+ exchanger (NCX1) in exchange for sodium, the
activity of which is closely coupled to the activity of the Na+,K+ ATPase and accessory protein phospholemman (PLM) (PLM). Calcium is
also removed from the cell by the plasma membrane Ca2+ ATPase (PMCA) and the mitochondrial Ca2+ uniporter (MCU), to a lesser extent.
Adapted from (Bers, 2002) [160].
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helix after the fourth transmembrane domain of
zDHHC5 that binds to NCX1. Recruitment of
zDHHC5 to PLM is mediated by the catalytic NKA
a-subunit, whose third intracellular loop interacts with
zDHHC5 (raising the possibility that PLM homo-
logues expressed in other tissues are also palmitoylated
by zDHHC5 after it is recruited by the NKA a-sub-
unit) [57,63,64]. A proximity biotinylation screen of
zDHHC5 recently identified zDHHC20 and O-
GlcNAc transferase as zDHHC5 interactors, and post-
translational modifications of zDHHC5 by these inter-
actors regulate NKA binding and PLM palmitoyla-
tion. zDHHC20 palmitoylates a dicysteine motif
(zDHHC5 C236 & C237) immediately on the N-termi-
nal side of the Na/K ATPase binding site to enhance
zDHHC5 interaction with the Na/K ATPase and
palmitoylation of PLM. O-GlcNAc transferase
GlcNAcylates zDHHC5 S241 and also enhances PLM
recruitment and palmitoylation [64].
Importantly, zDHHC5 palmitoylation of sarcolem-
mal substrates such as PLM has been implicated in the
pathophysiology of myocardial infarction, which is
caused by reperfusion of cardiac tissue after a period
of oxygen deprivation. In multiple cell types, including
fibroblasts and cardiac myocytes, calcium overload
during the reperfusion phase when oxygen is reintro-
duced leads to mitochondrial redox stress, causing
mitochondrial permeability transition pore opening
and release of Coenzyme A into the cytoplasm, which
is immediately acylated into a substrate for zDHHC5.
zDHHC5 palmitoylates plasma membrane proteins,
including PLM, causing their clustering in the surface
membrane. This triggers the process of massive endo-
cytosis (MEND), in which up to 70% of the cell sur-
face membrane is internalised and is crucial to the
damage caused during reperfusion [65]. Proteins pref-
erentially palmitoylated and internalised in this process
include ion transporters such as NKA and NCX1,
which typically have bulky intracellular regions that
can be accommodated in curved membrane domains
[52,55] (for which palmitoylated proteins display a
high affinity [66]). zDHHC5 and PLM knockout
mouse hearts and myocytes show reduced MEND and
enhanced functional recovery following anoxia-reper-
fusion, strongly implicating zDHHC5 as a key media-
tor in this process [67]. The dependence of this
extensive plasma membrane remodelling on acyl-CoA
synthesis suggests that fatty acyl-CoA availability is
one factor that limits (and therefore controls)
zDHHC5-mediated palmitoylation of substrates.
Evidently then, the positioning and post-transla-
tional modifications of the NKA and NCX1-interact-
ing ‘substrate recognition helix’ in zDHHC5 are
important regulators of substrate recruitment, and ulti-
mately therefore substrate palmitoylation. A recent
study has also established that the enzymatic activity
of zDHHC5 can be directly inhibited by phosphoryla-
tion of a conserved tyrosine in the same intracellular
loop as the zDHHC5 active site [68]. With zDHHC5
subcellular localisation [69,70], acyl-CoA availability
[67] and adaptor protein interactions [61,62] also estab-
lished to regulate substrate recruitment, the complexity
of the zDHHC5 upstream regulatory milieu grows ever
more convoluted.
Palmitoylation of pathogen and parasite proteins
Understanding the role of palmitoylation in toxins,
parasites and infectious diseases is an area of increas-
ing interest, particular due to the recent SARS-CoV-2-
mediated pandemic. In terms of toxins, recent evidence
implicated zDHHC5 as a central factor in the mecha-
nism of action of anthrax toxin through microdomain
partitioning [71], while discovery of a large portion of
the Plasmodium falciparum palmitome suggests palmi-
toylation may play a significant role in regulation of
its parasitic function [72].
Viruses hijack host machinery to modify their own
proteins for the benefit of viral replication, and their
ability to use palmitoylation machinery to modify their
own viral proteins was first discovered in 1979. Since
then, the majority of research has focussed on the role
of palmitoylation in enveloped viruses (reviewed by
Sobocinska, et al. 2018 [73]), viruses surrounded by a
glycoprotein rich lipid bilayer, of which the SARS-
CoV-2 virus is classified. Several SARS-CoV-2 proteins
are palmitoylated and have been found to associate
with zDHHC-PATs using proximity biotinylation,
with zDHHC3 and zDHHC13 the most commonly
identified in the vicinity of viral proteins [74]. The
SARS-CoV-2 spike protein uses its receptor binding
domain to bind to angiotensin-converting enzyme 2
receptors and invade host respiratory cells, and there-
fore, mechanisms to prevent spike function or interac-
tions may be therapeutically beneficial [75].
Interestingly, research several years ago identified spike
protein S-palmitoylation in SARS-CoV-1 and investi-
gated four cysteine clusters, some of which were
important for spike expression and viral fusion [76,77].
Experimental tools
Techniques to measure protein palmitoylation
Multiple techniques have been developed to investigate
protein palmitoylation. Some are capable of providing
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a snapshot of steady-state palmitoylation levels in the
cell, whereas others can report on palmitoylation
dynamics. It is important to be aware of the limita-
tions of each technique and in particular, the questions
that cannot be addressed using the techniques avail-
able.
Radiolabelling
The palmitoylation field was limited for several years
due to a lack of experimental tools. Developed in the
1980s [78], radioactive assays labelling the cellular pool
of fatty acids with [3H]-palmitate, followed by purifica-
tion, electrophoresis and autoradiography, were com-
monly used in live cells. Although beneficial in
allowing pulse-chase identification of palmitoylation
turnover, including demonstrating the rapid activation-
driven depalmitoylation of H-ras [79], these techniques
were limited in the information they could give on
palmitoylation stoichiometry, and were often laborious
and time consuming. In particular, these experiments
typically employed mCurie quantities of [3H]-palmitate
and required exposure of dried gels to X-ray films for
many weeks. For researchers more accustomed to the
rapid turnaround of experiments, for example employ-
ing 32P labelling of phosphoproteins, it was common
for autoradiographs to come out frustratingly blank
unless they lay forgotten for many months in the
80˚C freezer. As such, [3H]-palmitate is no longer
widely used in the field, but remains the ‘gold stan-
dard’ technique to demonstrate lipidation modifica-
tions in general [80]. However, there is potential for
incorporation of labelled palmitate into serine/thre-
onine residues via oxyester linkage [81]. Additionally,
given the preference of some zDHHC-PATs for fatty
acid chain lengths other than 16-carbon and the fact
that extended incubation periods with [3H]-palmitate
can lead to the labelled palmitate being metabolised
and entering different pools of cellular fatty acids,
there are weaknesses to this approach that must
always be considered [14].
Affinity purification
The chemically inert nature of palmitate and fatty
acids in general limited efforts to affinity purify lipi-
dated proteins for many years. The development of
the biotin-switch technique, now routinely used to
identify numerous cysteine PTMs in both cells and tis-
sues, enabled affinity purification and proteome-level
characterisation of palmitoylated proteins using an
approach referred to as acyl-biotin exchange (ABE)
[82]. This approach relies on alkylation of free
cysteines (most commonly with N-ethylmaleimide)
under denaturing conditions, specific cleavage of the
thioester bond between palmitate and the palmitoy-
lated cysteine (most commonly with neutral hydroxy-
lamine), reaction of the newly revealed cysteines with a
sulfhydryl-reactive biotinylation reagent and finally
affinity purification of biotinylated proteins using
streptavidin beads (Fig. 4).
In a similar vein, the technique of acyl-resin-assisted
capture (Acyl-RAC), a refinement of ABE, dispensed
with the biotinylation step and instead combined the
thioester cleavage and capture steps utilising 2-thiopy-
ridyl disulphide-containing thiopropyl Sepharose beads
(Fig. 4) [83]. Both Acyl-RAC and ABE are widely
used as they allow direct assessment of the fraction of
a particular protein in a cell or tissue that is palmitoy-
lated – by comparing the degree of enrichment of that
protein compared to the initial unfractionated cell
lysate. Both techniques are labour-intensive however,
with clean-up steps (either precipitation or desalting)
required after cysteine alkylation and cysteine biotiny-
lation. A refinement, in which cysteine alkylation is
followed by chemical scavenging of N-ethylmaleimide
using 2,3-dimethyl-1,3-butadiene in an aqueous Diels-
Alder 4 + 2 cycloaddition reaction, removed the need
for any clean-up steps but has not yet been widely
adopted [84].
All these techniques efficiently purify all palmitoy-
lated proteins from a cell lysate providing an accurate
‘snapshot’ of steady-state palmitoylation levels in the
cell, but are limited in that they cannot provide infor-
mation on palmitoylation/depalmitoylation dynamics,
nor are they capable of detecting changes from singly
to multiply palmitoylated states. Two factors, achiev-
ing complete alkylation of free cysteines and the speci-
ficity of the thioester cleavage step, are central to the
success of this approach. To avoid false positives, it is
important to consider the nature of the protein of
interest. Proteins containing multiple disulphides evade
initial alkylation, leaving them free to disulphide
exchange with the thiopyridyl disulphide group, and
therefore, an initial reducing step utilising 1,4-Dithio-
threitol (DTT) or tris(2-carboxylethyl)phosphine
(TCEP) can prevent this. In terms of hydroxylamine
specific cleavage, conducting duplicate assays in which
hydroxylamine is omitted from one reaction can con-
firm specificity. It is also important to be aware that
hydroxylamine-dependent affinity purification of a
protein is evidence that a thioester bond exists in that
particular protein, which is only indirect evidence that
it is palmitoylated. Thioesters are common in active
site cysteines, for example GAPDH [85], and universal
to E3 ubiquitin ligase enzymes [86], and these may be
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purified in an Acyl-RAC reaction even if no palmitoy-
lation occurs.
Antibody-based approaches
Although both affinity purification techniques allow
evaluation of the acylated fraction of a protein, they
cannot distinguish between fatty acid chain length and
detect palmitoylation exclusively. As such, there has
been attempts to generate specific antibodies that
detect protein palmitoylation, but these have been lar-
gely unsuccessful due to the difficultly in raising an
antibody against the hydrophobic modification.
Indeed, there are very few examples of antibodies
specific to cysteine post-translational modifications
being successfully produced (although see [87]), and
despite extensive efforts we have failed to develop such
tools. A recent study reports a pan-palmitoylation
antibody for the detection of the palmitoylated frac-
tion of a protein, but this has yet to be widely trialled
or adopted [88].
Cysteine PEGylation
A useful adaptation of the ABE/Acyl-RAC assay is to





























































































Fig. 4. Nonradiolabelled methods of detecting protein palmitoylation. In an effort to provide safer alternatives to radioactive palmitoylation
assays, purification methods such as acyl-biotin exchange (ABE) and Acyl-RAC-assisted capture (Acyl-RAC) and click chemistry-based
detection techniques have been developed. ABE and Acyl-RAC involve alkylation of free cysteines with either N-ethylmaleimide (NEM) or
methylation with S-methyl methanethiosulfonate (MMTS), followed by cleavage of thioesters at acylation sites with hydroxylamine (HA). For
ABE, this is followed by incubation and conjugation of a HPDP-biotin molecule to the newly freed cysteine, and purification with streptavidin
containing beads of agarose, whereas for Acyl-RAC, the freed cysteine can be immediately conjugated to thiopropyl sepharose containing
beads. By comparing initial lysate (unfractionated), percentage palmitoylation of any proteins in the sample can be determined by SDS-
PAGE. Click chemistry utilises the cells palmitoylation machinery to conjugate an alkyne-containing fatty acid (commonly 17-ODYA to detect
palmitoylation), followed by incubation with an azide-containing click chemistry probe, with a suitable detection system attached (biotin or
fluorescence), which can then be analysed via SDS-PAGE or fluorescence microscopy. All three techniques can be combined with mass
spectrometry to give unbiased, comprehensive indication of palmitoylated proteins.
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weight shift after the hydroxylamine cleavage step.
Rather than allowing capture of palmitoylated pro-
teins, this causes a ‘laddering’ of the protein of inter-
est, detected using SDS-PAGE and western blot
[63,64]. The extent of the laddering is dependent on
the number of palmitoylation sites occupied in the
protein, and the stoichiometry of palmitoylation. Com-
mercially available cysteine-reactive PEG maleimides
inducing a 5 kDa or 10 kDa molecular mass shift are
commonly used. In our hands, application of this tech-
nique is limited to proteins that migrate on SDS-
PAGE as single discrete bands smaller than 100 kDa
in size. Despite this limitation, PEGylation is the only
reliable method to count palmitoylation sites in pro-
teins, and to detect transitions between singly and mul-
tiply palmitoylated states.
Click chemistry
Driven by an effort to steer away from radioactivity
methods, the development of chemical probes for the
detection and characterisation of palmitoylated pro-
teins using click chemistry was a significant advance-
ment in the field, and remains a widely used method
(reviewed in Gao and Hannoush, 2018 [89]). The first
use of this technique involved an array of azido-con-
taining fatty acids of different carbon lengths, which
can metabolically incorporate into appropriate acyla-
tion sites (commonly 17-octadecyonic acid (17-
ODYA) for palmitoylation [90]). This is followed by
Cu(I)-catalysed [3 + 2] Huisgen cycloaddition or
‘clicking’ to a suitable alkyne-containing detection
system (biotin or a fluorophore) and analysis using
electrophoresis or fluorescence microscopy (Fig. 4)
[91]. Both azido and alkyne versions of the probes
exist, representing a host of lipid modifications, and
in terms of palmitoylation have been crucial in identi-
fying novel palmitoylated proteins, confirming sites of
modification and aiding in the understanding of fatty
acid selectivity, where probes of carbon length 14–18
and zDHHC-PAT preference were characterised and
manipulated through mutagenesis [92]. Indeed, adop-
tion of click chemistry has led to significant develop-
ments across many fields. For example, the azido-
palmitic acid probes revealed the functional role of
palmitoylation in tumour necrosis factor alpha [93]
and epidermal growth factor receptor [94] signalling
(facilitated through zDHHC20) [95], which may lead
to new therapeutic approaches for K-ras-positive lung
cancer.
However, there are limitations to this technique
that must be considered, including that electrophore-
sis of whole-cell click-chemistry experiments may limit
the detection of proteins palmitoylated with low stoi-
chiometry, and therefore may require additional
purification steps or coupling with more sensitive, yet
costly, proteomic analysis, to yield clear results. Our
own unpublished experience with these probes is that
certain cell types, cardiac myocytes in particular, do
not consistently incorporate them into the palmitoyl
proteome. The existence of a rigid cell wall in plant
cells also impairs probe uptake and incorporation.
Additionally, the commonly used 17-ODYA presents
several experimental caveats which may limit use, as
it has been reported to nonspecifically label N-myris-
toylation sites (likely involving the incorporation of
metabolic products from 17-ODYA degradation into
these sites [90]), as well be incorporated into glyco-
sylphosphatidylinositol moieties of proteins [96]. With
an ever-growing array of probes available, it is
important to also consider the functional conse-
quences of the azido/alkyne addition to the
hydrophobicity of the fatty acid and therefore its
affinity for the membrane and representation of
endogenous acylation. Fortunately, these probes are
extensively characterised (reviewed by Hannoush and
Sun, 2010 [97]) with study suggesting that alkyne
labelled fatty acids may incorporate more effectively
into proteins [98], and then, azide detection systems
may have a greater efficiency [99]. As with affinity
purification, precautions such as confirming the speci-
ficity of the reaction with neutral hydroxylamine
should be considered.
Nevertheless, click chemistry is a valuable tool in a
palmitoylation researcher’s arsenal, as where affinity
purification techniques cannot provide information on
palmitoylation turnover, click chemistry can be utilised
through control of probe incubation [100], and is
reported to produce a much lower proportion of false
positive compared to ABE [90]. The combined use of
these techniques when investigating any novel palmi-
toylated protein appears crucial, as recent evidence
suggests the estimated stoichiometry of protein palmi-
toylation can vary between techniques [101]. Currently,
click chemistry is limited to analysis of lysed or fixed
cells and its development in the field of live cell and
in vivo imaging would be invaluable, allowing spa-
tiotemporal tracking of palmitoylated proteins, signifi-
cantly enhancing our understanding of this dynamic
modification. Nonetheless, recent advancements in
coupling click chemistry with high and even superreso-
lution microscopy [102] and its use in the generation
of a high throughput small molecule screen for palmi-
toylation modulators [103] is promising. Additionally,
click chemistry, as well as affinity purification tech-
niques, are becoming more accessible and applicable
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to scientific projects due to the researcher-led develop-
ment of commercial assay kits [104].
Advances in quantitative proteomics
The above techniques can be successfully used to con-
firm selected, candidate S-acylated proteins using west-
ern blotting as an endpoint. However, by combining
with mass spectrometry (MS)-based proteomics tech-
niques, an unbiased, comprehensive list of acylated
proteins can be elucidated from a number of cell and
tissue types. This technique aided in the first substan-
tial global profiling of palmitoylated proteins in yeast
[27], whereby tandem MS analysis after purification in
the presence and absence of hydroxylamine identified a
host of novel S-acylated proteins. Additionally, adapt-
ing a quantitative approach for MS analysis allowed
consideration of the relative abundance of detected
peptides between duplicate purifications conducted in
the absence and presence of hydroxylamine. This is an
important refinement as it limits the number of false
positives and negatives (proteins / peptides purified in
the absence of hydroxylamine) [105]. Given the excep-
tional sensitivity of MS-based approaches, we caution
researchers to always consider whether a biologically
meaningful fraction of their protein of interest is
palmitoylated. The presence of a particular protein in
a list of several thousand proteins identified by MS is
no guarantee that palmitoylation of the protein in
question merits investigation. Spurious palmitoylation
sites and false positives are often observed [106], less
frequently reported.
A significant advantage afforded by the MS-based
approach is the opportunity to gain information about
palmitoylation sites. Broadly speaking, there are two
ways to achieve this. Tryptic digestion immediately
before or immediately after affinity purification using
acyl-RAC or ABE will capture only palmitoylated
peptides for MS detection. Using this approach, all
peptides detected will contain cysteines, so for those
peptides containing a single cysteine the palmitoylation
site is identified. Using acyl-RAC and ABE this tech-
nique identified 84 and 168 palmitoylation sites,
respectively, in affinity-purified peptides from mam-
malian cells [83,107]. Alternatively, a differential alky-
lation approach can be used, in which the initial
cysteine alkylation/block step (Fig. 4) employs one
alkylating agent, and previously palmitoylated cys-
teines are alkylated with a different reagent (or left in
the reduced state) after capturing intact proteins by
acyl-RAC or ABE. To successfully identify palmitoyla-
tion sites, the differential alkylation approach requires
good protein coverage in the MS analysis. The most
comprehensive example of this, which identified 906
palmitoylation sites in mouse forebrain [108], repre-
sents an important resource for the field.
Quantitative MS was first used to investigate the
extent of palmitoylated substrates in neurons, where
seminal work demonstrated dramatic remodelling of
the synaptic palmitome associated with neuronal activ-
ity, [109] and opened the door to a renaissance for the
field of dynamic palmitoylation. Acyl-RAC and ABE
have now catalogued tissue and cell palmitomes in mul-
tiple tissues (curated in the SwissPalm database [8]), as
well as assisting in the identification of enzyme/sub-
strate pairs. For example, label-free MS analysis of
palmitoylated proteins prepared using acyl-RAC from
the liver in the presence and absence of zDHHC13
(which is associated with abnormal liver function) iden-
tified substantial remodelling of the palmitome caused
by the absence of a single PAT [110]. In fact, as well as
identifying novel palmitoylated proteins, this technique
has been applied to identify substrates of numerous
zDHHC-PATs in the setting of cancer [111] and neu-
ronal development [112].
Quantitative proteomics are not just been restricted
to acyl-RAC and ABE, with several click chemistry
probes available to combine pulse-chase methods with
MS techniques [89]. The first such study used Stable
Isotope Labelling by Amino acids in Cell culture
(SILAC) in combination with 17-ODYA labelling to
reveal the global palmitoylation dynamics in mouse
T-cell hybridoma cells [113]. Not only did this investi-
gation aid in our understanding of palmitate cycling
on heterotrimeric and small G proteins such as H-ras
and N-ras, it also identified chemical tools to probe
the behaviour of depalmitoylating enzymes. The
insights into palmitoylation dynamics afforded by
applying quantitative MS in combination clickable
palmitate analogues are consequently formidable. For
those interested in cellular dynamics and signalling
events, being able to visualise the global turnover the
palmitome supports easy identification of proteins of
interest.
Tools to pharmacologically manipulate protein
palmitoylation
Once palmitoylation of a target protein is established,
altering its palmitoylation pharmacologically in order
to understand elucidate the functional consequences is
beneficial. Similarly to the development of detection
methods, this field was limited for many years due to
lack of suitable tools and only now are more robust
methods beginning to replace more crude techniques
once employed.
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Inhibiting zDHHC-palmitoyl acyltransferases
As will be discussed, zDHHC-PATs can show some
form of redundancy, limiting the information gained
from individual knockout models on their function
and any subsequent change in substrate behaviour.
Pharmacologically inhibiting a select zDHHC-PAT for
shorter periods of time would be informative; however,
attempts to make zDHHC-PAT specific inhibitors, tar-
geting the active site, have not been fruitful thus far.
This is due to the lack of structural understanding of
these integral membrane proteins, including difficultly
in resolving high resolution structures. However, this
was recently achieved for both zDHHC15 and
zDHHC20 [114], in part through utilisation of the gen-
eral zDHHC-PAT inhibitor 2-bromopalmitate (2-BP).
Often referred to as a ‘suicide inhibitor’, 2-BP, which
is thought to irreversibly alter the zDHHC active site
cysteine through nucleophilic displacement and alkyla-
tion, has been widely used to determine the effect of
reducing palmitoylation on proteins of interest [115].
However, there are several caveats to its use including
poor potency and bioavailability, which limits transla-
tional studies, and several groups have now docu-
mented its extensive off-target effects, suggesting up to
99% of its targets are not zDHHC-PATs [116]. Addi-
tionally, its exact mechanism of action is still
unknown. Some of its cellular effects are caused by
altering lipid metabolism, and it has long been known
to inhibit mitochondrial fatty acid oxidation indepen-
dent of any influence on zDHHC-PATs [117]. This is
supported by mass spectrometry suggesting it does not
favour zDHHC-PATs over other proteins
[116,118,119]. Interestingly, it may also paradoxically
inhibit depalmitoylation through APT1 [120]. Despite
this, it is still widely used due to lack of suitable alter-
natives, frequently at concentrations above its IC50 of
10µM [115], and therefore, caution must be applied in
concluding any functional effects from its use.
Additionally, lipid-based alternatives such as antibi-
otics tunicamycin, which has been shown to inhibit the
palmitoylation of calcium channels [121] and presynap-
tic plasticity protein GAP-43 [122], and cerulenin,
which has been reported to inhibit palmitoylation of
fatty acid uptake channel CD36 [123], can be used.
However, again these remaining relatively uncharac-
terised in terms of mechanism of action and off-target
effects. As will be discussed, more recent attempts to
identify inhibitors have utilised high throughput
screening, including pharmacological control over
DHHC-PAT active site autopalmitoylation although
their broader effectiveness still remains to be deter-
mined [124].
Inhibiting acylthioesterases
Another route through which palmitoylation can be
influenced is through inhibiting depalmitoylation. As
the first described acylthioesterase, efforts to find an
inhibitor of APT1 lead to the development of palmo-
statin-B, through comparing structural similarities of
APT1 to gastric lipase and basing a compound screen
on features of an inhibitor of the latter [125]. Palmo-
statin-B reversibly inhibits and inactivates APT1, and
inhibited depalmitoylation of H-ras and N-ras leading
to loss of membrane and Golgi localisation [125]. The
specificity of this particular tool compound for APT1
is questionable, given the finding that palmostatin B
but not ML-348 inhibits depalmitoylation of N-ras
[21]. It is now generally accepted that palmostatin B
acts as a rather broad spectrum thioesterase inhibitor,
targeting APT1 and APT2 as well as serine hydrolases
in the ABHD family [21]. ML-348 specifically targets
APT1, and ML-349 inhibits APT2 [126]. Given the
in vivo bioavailability of these compounds it is perhaps
surprising that to date relatively few studies have used
them to specifically target depalmitoylation in animal
models. For palmostatin-B, this again could be largely
due to reported off-target effects [21,127] and poor
drug-like properties resulting in lack of stability [18].
ML348 and ML349 often report more specific inhibit-
ing activity evidenced by results from siRNA experi-
ments [128] and show more promise in their use in vivo
[126,129].
Novel approaches
Although inhibitors targeting the active site of
zDHHC-PATs and acylthioesterases would no doubt
provide valuable research tools, each individual
enzyme can have several varied targets in a cell or tis-
sue and specifically targeting the interaction between
zDHHC-PAT/acylthioesterase and substrate may be
more therapeutically relevant. Although, as will be dis-
cussed, the recognition rules for zDHHC-PAT and
substrate are still undetermined, evidence suggests
unique features such as SH3 regulatory domains or
ankyrin repeats may play a role. This was elegantly
demonstrated over a decade ago with Golgi-localised
zDHHC17 whereby fusion of its ankyrin repeat
domain to zDHHC3 enabled it to interact and palmi-
toylate zDHHC17 substrates [130]. Additionally, we
have shown recently that it is possible to selectively
disrupt the zDHHC5-mediated palmitoylation of PLM
through blocking the aforementioned direct interaction
of the PAT with NKA. Using peptide array technol-
ogy, we identified the key residues of zDHHC5
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involved in interaction with the NKA and designed a
stearate-tagged cell-penetrating peptide disruptor
which reduced PLM palmitoylation in both HEK293
and cardiac myocytes [64]. Being able to selectively
disrupt palmitoylation of PLM to increase NKA activ-
ity may represent a novel treatment strategy for heart
failure and cardiac hypertrophy [57]. Of course, pep-
tide disruptors are limited therapeutically due to their
often poor bioavailability and pharmacokinetic proper-
ties, but may pave the way to understanding how to
produce small molecule drugs to target these interac-
tions specifically, and provide powerful tools for
understanding palmitoylation mechanisms.
Additionally, several groups have investigated the
use of classic and novel compounds to drive an
increase or decrease in palmitoylation. The simplest
possible example of this is palmitate supplementation,
which enhances the palmitoylation status of some pro-
teins in cell culture [46,49]. However, the broad appli-
cability of this approach to all cell types and in vivo is
questionable. Fatty acid excess, for example following
high fat diet, has been found to drive reduced palmi-
toylation of H-ras as a result of mitochondrial redox
stress [131]. In the presence of reactive oxygen species
cysteines that are depalmitoylated can be reversibly or
irreversibly oxidised, reducing the palmitoylation of
the protein of interest in the presence of excess palmi-
tate.
A well-established technique to determine the effect
of loss of palmitoylation of individual substrate func-
tion is through site-directed mutagenesis, most com-
monly of the palmitoylated cysteine to an
unpalmitoylatable alanine. However recently, this
approach has been used to produce ‘gain of function’
palmitoylation mutants, including a novel ‘lipidation
mimic’ strategy which replaces the cysteine with the
most hydrophobic amino acid, tryptophan, in order to
mimic fatty acid attachment, which was able to par-
tially rescue the phenotype of an alanine mutant [132].
A recently published refinement of this approach used
unnatural amino acids (i.e. those formed from a codon
sequence not commonly used by cells, e.g. TAG)
whereby the amino acid is genetically introduced, with
either a strained alkyne/acyl-modified azide attached,
in replace of the cysteine. This amino acid can then be
conjugated in an inverse-electron-demand Diels-Adler
cycloaddition reaction to a fluorescent detection sys-
tem in live cells, providing a very powerful tool to
understand the functional effect of increased palmitoy-
lation on individual proteins [133] Although this is a
significant advance, especially due to lack of pharma-
cological compounds, mutation of palmitoylated cys-
teines may have unintentional consequences on other
cysteine modifications such a redox modifications S-
glutathionylation and S-nitrosylation, as it is typically
solvent exposed cysteines that participate in palmitoy-
lation and are thus open to additional post-transla-
tional modifications [134].
On the other hand, methods to enhance depalmitoy-
lation are also emerging. Using a cell penetrating,
amphiphillic compound, in order to optimise targeting
to the membrane, Rudd, et al. were able to show
depalmitoylation of H-ras in vitro. Importantly, use of
the compound in an in vivo model of infantile neuronal
ceroid lipofuscinosis (a degenerative disease caused by
mutations in the gene encoding depalmitoylation
enzyme palmitoyl-protein thioesterase 1 (PPT1))
showed that after treatment, once mislocalised pro-
teins, including GAP-43, were reduced. In theory, this
approach allows an understanding of global depalmi-
toylation without altering other functional aspects of
these proteins or the palmitoylation machinery [135].
The usefulness of in-vivo transgenic models to study
protein palmitoylation
Numerous transgenic animal models are now available
to investigate the importance of protein palmitoylation
in physiology and pathology. Perhaps reflecting the
redundancy of the zDHHC-PAT family, zDHHC
knockout animals reported to date are generally viable
and display relatively modest phenotypes (with the
notable exceptions of zDHHC8 [136] and zDHHC16
[48]). Several of these models exhibit behavioural
defects, reflecting the functional diversity and impor-
tance of synaptic zDHHC-PAT substrates. For exam-
ple, zDHHC17 knockout impairs glutaminergic
synapse function, leading to defects in hippocampal
memory and synaptic plasticity [137], and knockout of
zDHHCs 3, 5, 11, 23 and 24 all cause behavioural
and/or neurological defects, according to the Interna-
tional Mouse Phenotyping Consortium Database.
The Golgi-localised zDHHC-PATs zDHHC3 and
zDHHC7 are widely acknowledged to act as ‘high
capacity, low specificity’ palmitoylating enzymes in the
Golgi apparatus [138], where they share overlapping
substrates, for example heterotrimeric G protein alpha
subunits [139]. Interestingly, palmitoylation of the
zDHHC3 substrates GABA-A receptor c2 subunit and
GAP43 was modestly reduced but not abolished in
zDHHC3 knockout animals [140], suggesting that
other zDHHC-PATs are not capable of fully substitut-
ing for zDHHC3. This emphasises that knockout mod-
els have merit to identify enzyme/substrate
relationships between zDHHC-PATs and palmitoy-
lated proteins, albeit not offering a ‘black and white’
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picture as a result of the functional redundancy
between zDHHC-PATs. Importantly, dual knockout
of zDHHC3 and zDHHC7 causes perinatal lethality
[140] in the majority of animals, confirming the con-
cept of overlapping substrate specificities for these
enzymes.
The functional redundancy of zDHHC-PATs
remains a theme in other investigations. For example,
acute siRNA-mediated knockdown of multiple
zDHHC-PATs reduces large conductance calcium and
voltage-activated potassium channel palmitoylation
[141], but no single zDHHC-PAT is solely responsible
for palmitoylating this channel. Similarly, CRISPR-
mediated zDHHC5 knockout reduces but does not
abolish palmitoylation of NCX1 [49], while thirteen
different zDHHC-PATs were found to be capable of
palmitoylating Gai3 in an overexpression study [142].
Evidently, substrates are promiscuous in their choice
of zDHHC-PATs, and there remains much work to be
done to understand the ‘recognition rules’ that apply
within these relationships. Promiscuity appears to be
the rule whether a protein is a peripheral or integral
membrane protein. However, concept of ‘local palmi-
toylation’ for integral membrane proteins has recently
been proposed in which an important governing factor
in the enzyme/substrate relationship is co-localisation
of zDHHC-PAT and substrate [143]. It is certainly
conceivable that palmitoylated integral membrane pro-
teins that are generally confined to one subcellular
compartment during their functional lifetime may be
palmitoylated by a small number of zDHHC-PATs in
their ‘home’ compartment (e.g. NCX1 by zDHHC5),
while being palmitoylated by other enzymes during
their passage through the secretory pathway.
Future challenges
Substrate recognition rules
SwissPalm, a curated database of palmitoylated pro-
teins, which includes known palmitoylated proteins,
known palmitoylation sites, and enzyme/substrate rela-
tionships for palmitoylating and depalmitoylating
enzymes is a key resource for this field [8]. As
enzyme/substrate pairs are established and this data-
base matures, the opportunity to improve our under-
standing of zDHHC-PAT relationships with their
substrates will expand. To date, palmitoylation site
prediction algorithms based on palmitoylation sites
identified using proteomics have failed to offer signifi-
cant insight into the rules underlying substrate recogni-
tion. Substrate recognition rules for protein kinases
based on whole phosphoproteomic data would yield
little value, so it is little wonder that whole palmitome
analyses has failed here. We also suggest that the use
of scoring matrices based on the position of a particu-
lar palmitoylated cysteine relative to nearby amino
acids is not a sensible approach. Palmitoylation of
NCX1, for example, is completely unaffected when a
single amino acid is inserted between the palmitoylated
cysteine and the amphipathic a-helix recognised by the
NCX1 zDHHC-PAT [54]. Claudin-3 palmitoylation
can occur at multiple positions within its transmem-
brane region [144]. In other words, proximity but not
absolute position relative to a ‘palmitoylation signal’
in a protein dictates cysteine palmitoylation: the posi-
tional scoring matrices that served kinase biology so
well are no use for palmitoylation.
Where the palmitoylation field could learn some
tricks from the protein phosphorylation field is in the
rational design of derivatised substrates for engineered
zDHHC-PATs – the so-called ‘bump-hole’ strategy.
Pioneered by Kevan Shokat, this approach engineers
the kinase active site to accept an ATP derivative that
cannot be accommodated by wild-type kinases [145].
Use of this modified ATP by the kinase tags its sub-
strates for affinity purification and identification. Our
understanding of the structure of zDHHC-PATs [14],
and the way that the fatty acid substrate is accommo-
dated within the transmembrane domains [92] means
that engineering zDHHC-PATs that can accept a mod-
ified substrate is feasible. This would allow us to
definitively identify zDHHC-PAT substrates in multi-
ple cell types, paving the way for a deeper understand-
ing of the enzyme/substrate relationships, and offering
the potential to pharmacologically target these rela-
tionships.
Accessory Proteins and zDHHC-PAT regulatory
pathways
As we strive to further characterise zDHHC-PATs, it
is increasingly important to consider the influence of
accessory proteins, as they may provide novel routes
of targeting [146]. This has long been known from
study of zDHHC9, where co expression with accessory
protein GCP16 is essential to its activity [147]. Target-
ing this relationship may therefore offer an opportu-
nity to impair palmitoylation of ras isoforms. The
example of zDHHC5 is also relevant here. In some
model systems, this PAT relies on the accessory pro-
tein Golga7 [62] (the same protein as GCP16); in some
model systems, Golga7b [61] is present, and in other
systems substrates bind directly to the same region of
zDHHC5 as these accessory proteins [49,64]. The pres-
ence and absence of these proteins, their homologues
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and the activity of enzymes that post-translationally
modify substrate binding sites all contribute to
zDHHC5 regulation. We suggest that proximity
biotinylation, which successfully identified zDHHC20
and O-GlcNAc transferase upstream of zDHHC5, has
significant potential for unpicking zDHHC-PAT regu-
latory pathways, as well as identifying substrates [64].
In the case of several PATs, it is impossible to detect a
physical interaction with substrate using either affinity
purification or genetic screens [138]. We therefore pro-
pose that BioID and APEX not only offer the best
way forward to identify zDHHC-PAT interaction net-
works, but also to determine how these interaction
networks remodel during signalling and disease,
although it is important to consider that co-localisa-
tion or direct interaction of zDHHC-PAT and sub-
strate does not always infer substrate modification
(e.g. PSD-95 colocalises with zDHHC5 [28], but is not
palmitoylated by this enzyme [148]).
Importantly, zDHHC-PATs themselves are subject
to a host of PTMs, which adds to the complexity of S-
acylation as a modification. Although auto-acylation
of the active site cysteine is generally thought to be an
intermediate step in zDHHC-PAT catalysis, [149] addi-
tional S-palmitoylation has been reported to regulate
the activity of several zDHHC-PATs. S-palmitoylation
of zDHHC13 is reduced in a model of Huntington’s
disease and limiting the presence of its substrate, the
huntingtin protein, decreases its enzymatic activity
in vivo [150]. As mentioned, proximity biotinylation
revealed palmitoylation of zDHHC5 by zDHHC20,
which has knock-on effects on sodium pump recruit-
ment [64]. Additionally, several studies have shown the
interplay between S-palmitoylation and phosphoryla-
tion of transporters [151], ion channels [152] and regu-
latory proteins [56], and there is now increasing
evidence of phosphorylation-mediated control of
zDHHC-PAT function. Of note, LYN kinase-mediated
phosphorylation in the intracellular loop of zDHHC5
that contains the active site leads to its inactivation,
ultimately regulating CD36 palmitoylation in a feed-
back loop mechanism [68]. Phosphorylation of the
zDHHC5 C tail by the tyrosine kinase Fyn regulates
its subcellular localisation (and consequently substrate
interactions) in synapses [153]. Similarly, limiting
zDHHC3 tyrosine phosphorylation leads to increased
auto-acylation and substrate palmitoylation, with
implications for neuronal development [154].
Aside from PTMs, a few studies are beginning to
highlight the influence of microRNAs on zDHHC-
PAT activity. Expression zDHHC21, of which the
serotonin-1A receptor is a substrate, is negatively regu-
lated by miR-30e, levels of which are increased in the
postmortem brains of patients with major depressive
disorder with corresponding loss of serotonin-1A
palmitoylation [155]. Similarly, miR-134, a key modi-
fier in synaptic plasticity, was shown to regulate
zDHHC9 with potential knock-on effects for its sub-
strate H-Ras [156]. Clearly then, transcriptional con-
trol of zDHHC-PAT abundance, as well as post-
transcriptional and post-translational mechanisms all
require further investigation.
Better experimental tools
As mentioned above, the reliance of the palmitoylation
field on the compound 2-bromopalmitate (2-BP)
remains a significant barrier. Ultimately, we suggest
that the lack of specificity of this reagent risks under-
mining progress. While we acknowledge that pharma-
cological inhibitors of zDHHC-PATs are lacking, we
urge caution using 2-BP. This reagent is only suitable
to use alongside more specific genetic approaches to
impair palmitoylation of a protein of interest (e.g.
zDHHC-PAT silencing, palmitoylation site mutagene-
sis). Even if 2-BP were to be performing precisely as
intended (as a global palmitoylation inhibitor), the
value of experiments in which the entire cellular
palmitome is remodelled is questionable. Given the
well-established off-target effects, alternative reagents
are urgently required. Two recent high-throughput
screens measuring palmitoylation of dual leucine-zip-
per kinase [157] and ras [103] as endpoints have high-
lighted that zDHHC-PATs may be tractable to
inhibition by small molecules in compound libraries.
Similarly, a high-throughput screen for inhibitors of
yeast zDHHC Erf2 revealed compounds that could
inhibit PAT autopalmitoylation and Ras-dependent
growth [158]. While the conservation of the zDHHC-
PATs makes it unlikely that isoform-specific zDHHC-
PAT inhibitors targeting the active site can be found,
alternative approaches may bear fruit. The recent
report that substrate recruitment can be manipulated
offers hope that individual substrates could be tar-
geted. If there are isoform-specific differences in palmi-
toyl-CoA recruitment by the different zDHHC-PATs,
this may offer another route to pharmacologically tar-
get different PAT families.
Overall, although there are still many areas to
address, there is no doubt that the study of palmitoy-
lation has advanced significantly in recent years. With
constantly improving pharmacological options, experi-
mental models and understanding of palmitoylation
enzymology, our knowledge of the therapeutic rele-
vance of the modification, and the novel ways to by
which it can be modulated, will only increase.
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